文献速递垂体与肾上腺疾病

依维莫司治疗侵袭性泌乳素分泌型垂体腺瘤

Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

本文报道一例对卡麦角林、反复手术及放疗均难治的泌乳素瘤患者,加用超说明书依维莫司后5个月泌乳素下降且肿瘤退缩,12个月内肿瘤稳定。免疫组化显示泌乳素瘤mTOR通路激活,体外实验示依维莫司联合卡麦角林仅协同抑制泌乳素分泌。

要点

  • mTOR通路在泌乳素瘤中激活,依维莫司体外抑制肿瘤细胞增殖。
  • 难治性泌乳素瘤加用依维莫司可降低泌乳素并促肿瘤退缩。
  • 联合卡麦角林仅协同抑制泌乳素分泌,不协同抑制增殖。

核心结论

  • mTOR通路在泌乳素瘤中激活,依维莫司体外具抗增殖作用,可能成为部分常规治疗无效的侵袭性泌乳素瘤的新选择。

研究设计与样本

  • 病例报道一例难治性泌乳素瘤的超说明书依维莫司治疗,并行7例泌乳素瘤与11例尸检正常垂体组织的免疫组化比较及小鼠GH3细胞体外实验。

主要发现

  • 加用依维莫司后5个月泌乳素水平下降且肿瘤退缩,肿瘤稳定12个月,期间泌乳素虽升高但仍低于治疗前。
  • 患者肿瘤中磷酸化AKT、p-4EBP1和p-S6表达升高,7例泌乳素瘤较11例正常垂体组织核p-AKT、胞质p-S6及p-4EBP1表达增加。
  • GH3细胞中卡麦角林和依维莫司单药均抑制增殖与泌乳素分泌,联合仅协同抑制泌乳素分泌而不协同抑制增殖。

临床怎么用

  • 对卡麦角林、手术及放疗均难治的侵袭性泌乳素瘤,可考虑超说明书试用依维莫司并密切监测泌乳素与肿瘤大小。

局限性

  • 证据主要来自单例病例报道和体外细胞实验,样本量小,尚需更多临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Aggressive prolactin (PRL)-secreting pituitary adenomas that are resistant to conventional therapy with dopamine agonists, surgery, and radiation pose a therapeutic challenge. The mammalian target of rapamycin (mTOR) inhibitor everolimus is approved to treat neuroendocrine tumors (NETs), and cotreatment with the somatostatin receptor ligand octreotide improved median progression-free survival in patients with metastatic pancreatic NETs. PATIENT, INTERVENTION, AND RESULTS: We describe off-label everolimus treatment of a prolactinoma (PRLoma) refractory to cabergoline, repeat surgical resection, and radiation therapy. Addition of everolimus to cabergoline led to decreased PRL levels and tumor regression after 5 months. Tumor size remained stable for 12 months, and although PRL levels rose, they remained below pretreatment levels. Immunohistochemical (IHC) evaluation of expression of key mTOR pathway drivers of cell proliferation revealed elevated phosphorylated (p-)AKT, p-4EBP1, and p-S6 in the index patient's tumor. IHC analysis of seven additional PRLomas demonstrated increased expression of nuclear p-AKT, cytoplasmic p-S6, and globally increased p-4EBP1 in the PRLomas compared with 11 autopsy-derived normal pituitary tissues. In in vitro studies in murine mammosomatotroph tumor GH3 cells, we observed that both the dopamine agonist cabergoline and the mTOR inhibitor everolimus inhibited GH3 cell proliferation and PRL secretion as single agents, and the synergistic effect was noted with combination treatment only on inhibition of PRL secretion but not proliferation. CONCLUSIONS: In summary, our findings demonstrate that the mTOR pathway is activated in PRLomas and that everolimus exhibits antiproliferative actions in vitro. We suggest that everolimus may be a novel therapeutic option for some aggressive PRL-secreting tumors unresponsive to conventional treatments.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Zhang D, Way JS, Zhang X, et al. Effect of Everolimus in Treatment of Aggressive Prolactin-Secreting Pituitary Adenomas. J Clin Endocrinol Metab. 2019. PMID: 30624667. doi:10.1210/jc.2018-02461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。